Trials / Conditions / Non-24 Hour Sleep-Wake Disorder

Non-24 Hour Sleep-Wake Disorder

9 registered clinical trials studyying Non-24 Hour Sleep-Wake Disorder.

Status	Trial	Sponsor	Phase
Terminated	Biomarkers for Circadian Timing in Healthy Adults NCT03956745	Brigham and Women's Hospital	—
Terminated	Breath Biomarkers for Sleep Loss and Circadian Timing NCT03980340	Brigham and Women's Hospital	—
Completed	Study of the Pharmacokinetics and Safety of Tasimelteon in Children and Adolescents NCT02776215	Vanda Pharmaceuticals	Phase 1
Completed	Open Label Study to Assess the Absolute Bioavailability of Tasimelteon (HETLIOZ™) NCT02130999	Vanda Pharmaceuticals	Phase 4
Completed	Tasimelteon for the Treatment of Non-24-hour Sleep-Wake Disorder (N24HSWD) in Blind Individuals With no Light NCT01429116	Vanda Pharmaceuticals	Phase 3
Completed	Withdrawal Study to Demonstrate the Maintenance Effect in the Treatment of Non-24-Hour Sleep-Wake Disorder NCT01430754	Vanda Pharmaceuticals	Phase 3
Active Not Recruiting	Safety Study of Tasimelteon for Treatment of Non-24-Hour-Sleep-Wake Disorder in Blind Individuals With No Ligh NCT01218789	Vanda Pharmaceuticals	Phase 3
Completed	Efficacy and Safety of Tasimelteon Compared With Placebo in Totally Blind Subjects With Non-24-Hour Sleep-Wake NCT01163032	Vanda Pharmaceuticals	Phase 3
Completed	Efficacy and Safety of Circadin for Non-24 Hour Sleep-Wake Disorder in Totally Blind Subjects NCT00972075	Neurim Pharmaceuticals Ltd.	Phase 2